- +86-13363869198
- weimiaohb@126.com
Apr . 01, 2024 17:55 Back to list
Pharama Material Science and Manufacturing
Introduction
Pharama, in the context of pharmaceutical manufacturing, refers to a comprehensive system of single-use fluid handling solutions, encompassing sterile connectors, tubing, filter assemblies, and bioprocess containers. Its technical position within the biopharmaceutical industry chain is as a critical enabler of aseptic processing, moving away from traditional stainless steel systems towards increased flexibility, reduced cleaning validation requirements, and minimized cross-contamination risk. Core performance attributes include maintaining sterile integrity throughout the entire process, ensuring compatibility with a wide range of biopharmaceutical fluids, and facilitating efficient process transfer and scalability. The industry faces growing pressure to accelerate drug development and manufacturing timelines, coupled with stringent regulatory requirements. Pharama systems address these pain points by streamlining workflows, reducing downtime, and enhancing product quality. Critical challenges revolve around ensuring long-term material stability, preventing leachables and extractables from impacting product safety, and maintaining consistent performance across different manufacturing scales.
Material Science & Manufacturing
The core materials utilized in Pharama systems typically include multi-layer films composed of polyethylene (PE), polypropylene (PP), ethylene vinyl alcohol (EVOH), and polytetrafluoroethylene (PTFE). PE provides flexibility and weldability, PP offers chemical resistance and structural integrity, EVOH delivers an excellent oxygen barrier, and PTFE provides a low-friction, chemically inert surface. Raw material selection is paramount, focusing on USP Class VI compliance to ensure biocompatibility. Manufacturing processes involve film extrusion, layering, and welding techniques – often utilizing radio frequency (RF) or ultrasonic welding to create robust, leak-proof seals. Critical parameter control centers around maintaining weld integrity (weld strength exceeding fluid pressure), ensuring consistent film thickness to guarantee barrier properties, and controlling particulate matter generation during manufacturing. Specifically, the EVOH layer’s thickness must be precisely managed to optimize oxygen barrier performance without compromising flexibility. Furthermore, the absence of phthalates in plasticizers is vital due to their potential to leach into the process fluid. Post-weld testing, including leak testing and burst pressure testing, is routinely performed. Sterilization methods, predominantly gamma irradiation, require careful dose mapping to ensure sterility without causing material degradation.
Performance & Engineering
Performance assessment of Pharama systems hinges on several key engineering principles. Force analysis is crucial in evaluating the mechanical stress on connectors and tubing under fluid pressure and during handling. Finite Element Analysis (FEA) is often employed to predict stress distribution and identify potential failure points. Environmental resistance, particularly regarding temperature fluctuations and exposure to various cleaning and sanitization agents, is critical. Materials must maintain their integrity and barrier properties across a specified temperature range (typically -80°C to +50°C). Compatibility with a wide range of biopharmaceutical fluids – including proteins, buffers, and cell culture media – requires thorough testing for chemical compatibility and leachables/extractables. Regulatory compliance dictates adherence to standards such as USP <661.1> (Plastic Materials of Construction) and ISO 10993 (Biological Evaluation of Medical Devices). Functional implementation involves designing systems to optimize flow rates, minimize dead legs (areas where fluid can stagnate), and ensure complete drainage. The selection of appropriate connector types (e.g., luer locks, quick connects) is dictated by process requirements and operator ergonomics.
Technical Specifications
| Parameter | Unit | Typical Value | Test Method |
|---|---|---|---|
| Burst Pressure (Tubing) | psi | > 150 | ASTM D1599 |
| Oxygen Transmission Rate (OTR) | cc/m²/day | < 0.05 | ASTM D3985 |
| Water Vapor Transmission Rate (WVTR) | g/m²/day | < 0.1 | ASTM E96 |
| Leachables (Total Organic Carbon) | ppb | < 50 | USP <661.1> |
| Tensile Strength (Film) | MPa | > 20 | ASTM D882 |
| Elongation at Break (Film) | % | > 200 | ASTM D882 |
Failure Mode & Maintenance
Common failure modes in Pharama systems include connector failures (due to improper assembly or material fatigue), tubing cracks (resulting from excessive bending or exposure to incompatible chemicals), and weld failures (caused by inadequate weld parameters or material contamination). Fatigue cracking, particularly in areas subject to repeated stress, can lead to leaks. Delamination of multi-layer films can compromise barrier properties. Degradation of materials due to prolonged exposure to UV light or incompatible chemicals can result in embrittlement and failure. Oxidation can also affect the performance of certain materials. Preventive maintenance primarily involves visual inspection for signs of damage (cracks, discoloration, leaks), proper storage of components (protected from light and temperature extremes), and adherence to recommended usage guidelines. Regular pressure testing of assembled systems is recommended. Should a failure occur, a thorough root cause analysis should be conducted, including material testing and weld inspection, to prevent recurrence. Replacement of damaged components is generally preferred over attempting repairs, as maintaining sterility is paramount. Proper documentation of all maintenance activities is crucial for traceability and regulatory compliance.
Industry FAQ
Q: What is the impact of gamma irradiation on the mechanical properties of Pharama tubing?
A: Gamma irradiation can cause chain scission in polymer materials, leading to a reduction in tensile strength and elongation at break. The extent of this effect depends on the radiation dose, the polymer type, and the presence of stabilizers. Material suppliers typically provide data on the dose tolerance of their products, and it’s crucial to operate within those limits to maintain acceptable mechanical performance. Post-irradiation testing is recommended to verify material properties.
Q: How do you ensure the absence of phthalates in Pharama systems, given their potential as endocrine disruptors?
A: We rigorously vet our material suppliers to ensure they do not use phthalates as plasticizers. All incoming raw materials are subjected to stringent testing using gas chromatography-mass spectrometry (GC-MS) to verify the absence of phthalates at levels below regulatory limits. Certificates of Analysis (CoAs) are required for each batch of material.
Q: What measures are taken to mitigate the risk of leachables and extractables impacting product quality?
A: We employ a multi-faceted approach, including selecting USP Class VI compliant materials, optimizing manufacturing processes to minimize residual solvents, and conducting thorough leachables and extractables studies according to USP <661.1> and ISO 10993. These studies identify potential leachables and quantify their levels, ensuring they are below acceptable limits for the intended application.
Q: What is the recommended cleaning procedure for Pharama connectors if they require reuse (although single-use is preferred)?
A: While single-use is strongly recommended, if reuse is unavoidable, connectors should be thoroughly cleaned with a validated cleaning process using appropriate cleaning agents (typically water for injection (WFI) and a mild detergent). Connectors must be inspected for any signs of damage before and after cleaning. Sterilization is required after cleaning, typically via autoclaving or gamma irradiation, depending on material compatibility.
Q: How does the choice of connector material affect its compatibility with different biopharmaceutical fluids?
A: Connector material compatibility is critical. Certain fluids can cause swelling, degradation, or leaching of components from incompatible materials. For example, solvents can attack certain polymers, while proteins can adhere to hydrophobic surfaces. Materials such as polypropylene (PP) and polytetrafluoroethylene (PTFE) generally exhibit broad chemical compatibility. Thorough compatibility testing is essential to ensure the connector material does not compromise product quality or safety.
Conclusion
Pharama systems represent a critical advancement in biopharmaceutical manufacturing, offering significant advantages in terms of sterility, flexibility, and efficiency. The careful selection of materials, precise control of manufacturing processes, and rigorous quality control measures are paramount to ensuring reliable performance and maintaining product integrity. Ongoing innovation in material science and connector design will continue to drive improvements in Pharama technology, enabling faster drug development and more cost-effective manufacturing.
Looking ahead, the industry will likely see increased demand for Pharama systems with enhanced barrier properties, improved chemical resistance, and integrated sensor technologies for real-time process monitoring. The adoption of advanced analytical techniques for leachables and extractables detection will become increasingly important. The standardization of connector interfaces and the development of fully closed, automated bioprocessing systems will further streamline workflows and minimize the risk of contamination.